Skip to main content

Table 4 Results of univariate log-rank analysis of prognostic factors for progression-free survival and overall survival in 162 smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with TPF

From: Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil

Factors

No. of patients

Progression-free survival (PFS)

Overall survival (OS)

2-year PFS rate (%)

P value

2-year OS rate (%)

P value

Age

     

<53 years old

81

40

0.13

47

0.30

≧53 years old

81

46

 

56

 

Clinical 7th AJCC stage

     

IVA

80

46

0.62

58

0.30

IVB

82

41

 

45

 

Clinical T classification

     

T1 ~ 4a

92

44

0.77

55

0.49

T4b

70

42

 

46

 

Clinical N classification

     

N0/1

48

60

0.012*

69

0.003*

N2/3

114

36

 

44

 

Primary tumor site

     

Oral cavity

62

39

0.19

44

0.18

Others

100

46

 

56

 

Primary tumor site

     

Oropharynx

60

45

0.65

55

0.42

Others

102

42

 

49

 

Primary tumor site

     

Hypopharynx/Larynx

36

50

0.28

61

0.36

Others

126

41

 

48

 

Alcohol

     

Absent

16

56

0.25

69

0.29

Present

146

42

 

49

 

Betel nut chewing

     

Absent

31

67

0.004*

71

0.017*

Present

131

37

 

47

 
  1. TPF docetaxel, cisplatin, and fluorouracil
  2. *Statistically significant